Iran, a developing country with a population of approximately 71,000,000, is the most populous country in the Middle East and the 16th most populous in the world. Gross domestic product (GDP) per capita is US$8900 and total health expenditure is approximately 6% of GDP. The total number of end-stage renal disease (ESRD) patients reported by the Management Center for Transplantation and Special Diseases (MCTSD) was 32,686 in 2007, which denotes a prevalence of 466 per million population (pmp) in Iran. Considering the growth rate of 12%, the expected number of ESRD patients in 2010 is 40,000; incidence of ESRD is expected to be 63.8 pmp. These numbers are lower compared to developed countries, which may suggest poor referral and under-diagnosis of ESRD. In Iran at present, hemodialysis (HD) and renal transplantation are the most common renal replacement therapy (RRT) modalities, accounting for 47.7% and 48.8% of prevalent RRT patients respectively. Based on the Iran Dialysis Center report of 2001, approximately 1% of ESRD patients were being treated with continuous ambulatory peritoneal dialysis (CAPD); this number increased to approximately 3.5% (6.8% of total dialysis patients) in 2006. In the present article, reasons for underutilization of peritoneal dialysis (PD) and improvements in PD within the past 5 years will be reviewed.

Download full-text PDF

Source
http://dx.doi.org/10.3747/pdi.2008.00235DOI Listing

Publication Analysis

Top Keywords

peritoneal dialysis
12
esrd patients
12
continuous ambulatory
8
ambulatory peritoneal
8
dialysis
5
iran
5
esrd
5
patients
5
story continuous
4
dialysis iran
4

Similar Publications

Background: Fulminant myocarditis (FM) is a potentially lethal disease with a wide spectrum of clinical presentation, thus making the diagnosis hard to depict. In cases where acute circulatory failure occurs venoarterial (VA) extracorporeal membrane oxygenation (ECMO) support is a valid management strategy, especially in the pediatric and adult patients. This study aims to report the results of VA ECMO for FM in our Institution.

View Article and Find Full Text PDF

Rationale & Objective: Nearly half of kidney transplant recipients develop allograft failure within 10 years of transplantation and experience high mortality, significant symptom burden, and complex communication challenges. These patients may benefit from palliative care, but palliative care is infrequently provided in this population. This study explores palliative care perceptions and needs among patients with poorly functioning and declining kidney allografts.

View Article and Find Full Text PDF

Background: Few studies have evaluated the predictive capability of equations for residual kidney function (RKF) in patients undergoing peritoneal dialysis (PD). Moreover, the applicability of each equation remains unclear. Therefore, we aimed to evaluate the performances of the estimated RKF (eRKF) equations of Shafi, Steubl, and Jaques in Chinese patients undergoing continuous ambulatory peritoneal dialysis (CAPD).

View Article and Find Full Text PDF

Differences in dialysis modality choice between immigrant and native populations in Barcelona, Spain.

Nefrologia (Engl Ed)

January 2025

Servicio de Nefrología, Hospital del Mar, Instituto Hospital del Mar de Investigaciones Médicas, RD16/0009/0013 (ISCIII FEDER REDinREN), Barcelona, Spain; Servicio de Nefrología, Hospital Universitario 12 de Octubre, Madrid, Spain.

Few studies have analyzed the freedom to choose their renal replacement treatment (RRT) modality in Spain. In a total of 673 patients with ACKD (stage 4 and 5) seen at the outpatient ACKD clinic of Hospital del Mar, Barcelona, Catalonia (Spain) from 2009 to 2020, we retrospectively compared immigrant and Spanish patients in order to analyze the impact of migration on RRT decision-making and its subsequent evolution in advanced CKD (ACKD) consultation and identifies the social and economic needs of this population. One hundred thirteen (16.

View Article and Find Full Text PDF

Efficacy and safety of daprodustat in patients on peritoneal dialysis in the ASCEND-D trial.

Nephrol Dial Transplant

November 2024

Department of Medicine and Nephrology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

Background And Hypothesis: Daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is approved for treatment of anemia in dialysis patients with CKD in some parts of the world. This subgroup analysis examined the efficacy and safety of daprodustat versus darbepoetin alfa in patients with anemia of CKD undergoing peritoneal dialysis (PD).

Methods: ASCEND-D (NCT02879305) was an open-label, Phase 3 trial; patients with CKD were randomized to daprodustat daily and epoetin alfa (HD patients) or darbepoetin alfa (PD patients).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!